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The Effect of Individualised Homeopathic Treatment on Low Sexual Desire in 
Perimenopause 
 
ABSTRACT 
 
Purpose: The aim of the study was to ascertain the effect of individualised homeopathic treatment 
on low sexual desire in perimenopausal females between the ages of 40 and 60 years old.  
 
Method: This descriptive case study design recruited thirteen perimenopausal females between 
the ages of 40 and 60 by means of purposive sampling. Nine participants completed the study. 
Participants were treated with an individualised homeopathic remedy.  
 
Procedure: The study consisted of four consultations per participant over a period of 12 weeks. 
A single individualised homeopathic remedy was administered to each participant and the potency, 
dosage and frequency of administration was tailored to each person in accordance with the 
principles of classical homeopathy. The desire and arousal subscales of the Female Sexual 
Function Index (FSFI) was completed at each consultation in order to assess changes in sexual 
desire and arousal across time. Item 13 of the Female Sexual Distress Scale - Revised (FSDS-R) 
was utilised to assess changes in distress related to low sexual desire.  
 
Results: Results suggest that individualised homeopathic treatment may be beneficial in 
alleviating low sexual desire in seven out of nine perimenopausal females between the ages of 40 
and 60 years old.  
 
Conclusion: The results of this small pilot study suggest that individualised homeopathic 
treatment was effective in alleviating low sexual desire in perimenopause. The results also appear 
to confirm the beneficial effect of individualised homeopathic treatment on the additional 
symptoms associated with perimenopause. In order to verify the results, the study should be 
repeated using a larger sample group over a longer period of time.  
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INTRODUCTION 
 
Low sexual desire, or decreased libido, is one of the most prevalent sexual complaints in females 
and can affect both pre- and postmenopausal women (Kingsberg, 2010:2907). A study conducted 
in the United States showed prevalence rates of low sexual desire to be as high as 26.7% among 
premenopausal females and 52.4% among naturally menopausal females (West et al., 2008:1441). 
 
It is common for sexual desire in females to vary somewhat from day to day based on stressful 
events and other life influences. Many females however find that their interest in sex, as well as 
the intensity of their sexual desire, gradually decreases with age. This is often attributed to 
changing hormone levels as well as the genital changes associated with decreasing hormone levels 
which naturally occur with aging (Kingsberg, 2010:2907-2908). 
 
In some cases the decline in sexual desire may not be very severe and will therefore not have a 
major impact on a woman’s quality of life. In other cases the decrease or loss of sexual desire can 
be very distressing to the female (Kingsberg, 2010:2908). In cases where it is associated with 
personal distress and certain other criteria are also met, low sexual desire can be classified as 
Hypoactive Sexual Desire Disorder (HSDD) or Female Sexual Interest/Arousal Disorder (FSIAD) 
(American Psychiatric Association, 2000:n.p.; American Psychiatric Association, 2013:13). 
Research shows that clinicians associate HSDD with a vast array of emotional problems such as 
low self-esteem and feelings of inferiority, shame, anger, embarrassment and inadequacy, among 
others (Goldstein et al., 2009:1353).  
 
Currently there is no standard treatment for low sexual desire in females. Available treatment 
options include education, psychological therapy options and hormone replacement therapy (HRT) 
in cases where hormonal causes are suspected, such as during menopausal transition (Basson, 
2011:2525). Treatment options are however not equally effective and for many woman the risks 
associated with pharmacological treatments, such as hormone replacement therapy, often outweigh 
the benefits (Hendrix, 2011:2519; Presant, 2015:n.p.).  
 
Homeopathic treatment has shown to be beneficial for a variety of climacteric symptoms (Artemi 
et al., 2005:127; Buhling et al., 2013:96; Heymans et al., 2013:141), however there has been very 
little research conducted to date on its effect on low sexual function related to perimenopause. As 
a complementary medical approach, homeopathy is especially suited to treating all the symptoms 
of the perimenopausal period, including low sexual desire. Rather than focusing on isolated 
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symptoms, individualised homeopathy treats holistically and emotional symptoms are considered 
to be as important as the physical symptoms (MacEoin, 1997:xv). Homeopathic remedies are 
highly diluted, do not cause side effects, and are therefore deemed safe to use (De Schepper, 
2010:39). Further investigation however is required to determine the effect of individualised 
homeopathic treatment on female sexual function during menopausal transition. 
 
Prevalence of Low Sexual Desire in Perimenopause  
There are currently no South African statistics on low sexual desire however a study conducted by 
Grigoriou et al. (2013:125-127) on 1025 Greek women who were either perimenopausal or in their 
first five postmenopausal years, showed prevalence rates of 34.5% for sexual symptoms. Of the 
1025 females, 19.5% experienced a mild decrease in libido, 20.8% a moderate decrease and 18.8% 
a severe decrease. A review article written by Magon et al. (2012:63) concluded that 
perimenopausal women report significantly less sexual desire than premenopausal women. Rosen 
et al. (2012:505) also found a higher incidence of HSDD in peri-menopausal and early 
postmenopausal females.  
 
Pharmacological Treatment of Low Sexual Desire 
Currently no standard treatment for low sexual desire in females exists. In cases of low sexual 
desire where a clear aetiology exists, for example mood or endocrine disorders, the underlying 
cause should be addressed. Patients using SSRIs for depression whom subsequently suffer from 
sexual dysfunction, might benefit from switching to an anti-depressant with fewer sexual side 
effects. Low sexual desire specifically occurring as a symptom of menopause is traditionally 
treated with HRT (Basson, 2011:2523-2525). 
 
Katz et al. (2013:1807) tested Addyi® (flibanserin), a 5-HT1A agonist/5-HT2A antagonist, in 
premenopausal women with HSDD with promising results. The drug, initially developed as an 
anti-depressant, regulates levels of the sexual excitatory neurotransmitters dopamine and 
norepinephrine. It also produces a temporary decrease in serotonin, a sexual inhibitory 
neurotransmitter, in specific regions of the brain. Common side effects experienced by the 
treatment group included somnolence, dizziness and nausea, leading to 9.3% of the treatment 
group discontinuing use of the product due to adverse effects. 
 
On the 4th of June 2015, a joint committee expert panel for the FDA recommended that flibanserin, 
dubbed the “female Viagra” by the news media, be approved as the overall risk/benefit profile of 
the drug was acceptable. The drug failed in both 2010 and 2013 to be recommended for approval 
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(Andalo, 2015:n.p.). The current recommendation occurred amidst accusations of gender 
discrimination against the FDA. The panel itself described the benefit of the drug as “moderate” 
or “marginal”, but considering that no other approved treatment is currently available for HSDD, 
they agreed that the drug should be made available with appropriate warning labels and education 
(Schulte, 2015:n.p.; Presant, 2015:n.p.). The drug is not yet registered in South Africa (University 
of Cape Town, 2015:n.p.) 
 
Testosterone treatment for women with HSDD is being researched but remains controversial.  
There are approved testosterone therapies available for females in Europe, but currently not in the 
United States or South Africa. The American Endocrine Society recommends against the use of 
testosterone as safety and efficacy data pertaining to longer term use is not yet available (Basson, 
2011:252; Guidozzi et al., 2014:540). According to a review article by Davis and Braunstein 
(2012:1140, 1144-1145) testosterone therapy, either with or without concurrent oestrogen therapy, 
is effective in relieving the symptoms of HSDD in postmenopausal females. Concerns however 
exist that long term use in females could potentially damage the cardiovascular system, as well as 
stimulate endometrial and breast tissue, possibly leading to development of carcinoma. The studies 
they reviewed however showed that the most common adverse effects experienced with 
testosterone therapy was androgenic effects such as hirsutism and acne, with little adverse 
cardiovascular effects or stimulation of breast and endometrial tissue observed in low-dose 
therapy. Despite this, available safety data is not yet conclusive. 
 
Psychological Therapies 
A study conducted by Mintz et al. (2012:473,475) showed promising results for the use of 
bibliotherapy in low sexual desire that were, in the participant’s opinion, caused by stress and 
exhaustion. The intervention in this study consisted of reading a copy of a self-help book titled: 
“A Tired Woman’s Guide to Passionate Sex”. Females in the intervention group showed greater 
improvement in the desire, arousal and satisfaction domains as well as in general sexual 
functioning than women in the wait-list control (WLC) group, who only received the book after 
completing the post-test assessment. 
 
Brotto and Basson (2014:44, 50) tested the effect of a mindfulness-based cognitive behavioural 
sex therapy (MBCST) presented over four group-sessions. Mindfulness is an ancient practice 
which involves being aware of and accepting the present moment in a non-judgmental way. 
Mindfulness-based cognitive therapy (MBCT) has previously been shown to relieve anxiety and 
depression and also to prevent the relapse of depression. There is a strong link between depression 
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and HSDD, and females suffering from HSDD generally experience more depressed and anxious 
thoughts. They also tend to have a lower self-image and are more emotionally labile. Paying 
attention to the present moment can help females with HSDD increase their awareness of sexual 
responses as they unfold moment by moment, and can also help limit distracting thoughts, which 
can inhibit sexual arousal. In this study the females in the treatment group showed significant 
improvement in sexual function in the desire, arousal, lubrication and satisfaction domains when 
compared to the control group. This effect was still present at a six-month follow-up. 
 
According to Basson (2011:2525) women with sexual dysfunction associated with relationship 
problems may benefit from couples therapy.  
 
Herbal Treatment  
Akhtari et al. (2014:n.p.) demonstrated that Tribulus terrestris, or bindii, was effective in 
improving sexual function in premenopausal females suffering from HSDD. Participants showed 
significant improvement in their FSFI scores for the sexual desire, arousal and satisfaction 
domains. According to Gama et al. (2014:45, 48), the chemical substance protodioscin, which is 
converted into DHEA (an androgen), is derived from the Tribulus terrestris plant. Their study also 
demonstrated improvement in the sexual function of females treated with a daily dose of 250mg 
Tribulus terrestris extract.  
 
Ginkgo biloba extract (GBE) is a herbal extract which enhances blood flow, nitric oxide and 
further promotes smooth muscle relaxation, all of which are important components of proper 
female sexual function. Studies investigating the effect of GBE on female sexual desire have 
however produced conflicting results (Pebdani et al., 2014:262). Meston et al. (2008:17) found no 
beneficial effect beyond placebo in either short- or long term treatment with GBE in females with 
sexual dysfunction. The clinical trial conducted by Pebdani et al. (2014:265) however showed that 
GBE significantly improves sexual desire in menopausal women. 
 
MATERIALS AND METHODS 
Study Design 
This descriptive case study design consisted of four consultations per participant over a period of 
12 weeks. A single individualised homeopathic remedy was administered to each participant and 
the potency, dosage and frequency of administration was tailored to each person in accordance 
with the principles of classical homeopathy. 
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The desire and arousal subscales of the Female Sexual Function Index (FSFI) were completed at 
each consultation in order to assess changes in sexual desire and arousal across time. Item 13 of 
the Female Sexual Distress Scale - Revised (FSDS-R) was utilised to assess changes in distress 
related to low sexual desire. All consultations were supervised by a qualified homeopathic 
practitioner. 
 
Recruitment of Participants 
Thirteen perimenopausal females between the ages of 40 and 60 were recruited by means of 
purposive sampling. Advertisements were placed at the University of Johannesburg Doornfontein 
Campus, in local newspapers in Kempton Park and Edenvale, and at pharmacies and health shops 
in the Benoni area after relevant permission was obtained. 
 
Participants had to meet the following criteria in order to be included in the study: 
 Females, aged 40-60 years, who were perimenopausal (up to one year after final menses); 
 Low sexual desire present for at least three months; 
 At least two of the additional common signs and symptoms of perimenopause present for at 
least three months such as menorrhagia, irregular menses, amenorrhoea, hot flushes, night 
sweats, heart palpitations, insomnia, fatigue, mood swings, irritability, anxiety, memory and/or 
concentration loss, headaches, joint pain and vaginal dryness; and 
 A history of normal libido, with onset of low sexual desire coinciding with or appearing after 
the onset of other symptoms of perimenopause.  
 
Participants were excluded from the study if they had had: 
 Cessation of menses for more than one year (postmenopause); 
 A total hysterectomy; 
 Early menopause (before age 40); 
 Pelvic or abdominal surgery in the preceding six months; 
 Gynaecological disorders such as endometriosis, uterine fibroids, dyspareunia or vaginismus; 
 Chronic diseases that affected sexual desire; 
 Made use of chronic medications that could have affected sexual desire: HRT; oral contra-
ceptives; anti-depressants; benzodiazepines; beta-blockers; opioids; carbamazepine (anti-
seizure drug) or antihistamines; or 
 Pregnant or lactating women or childbirth in the preceding 12 months. 
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Data Collection and Analysis 
During the course of the study the relevant subscales of the FSFI as well as Item 13 of the FSDS-
R were completed at four weekly intervals by each participant. The participants were given a new 
form to complete at each consultation and did not have access to previously completed forms.   
 
All the qualitative data was obtained by means of case-takings and follow-up consultations. The 
data was then utilised to repertorise the case by means of Mercurius Repertorisation Software 
Complete Repertory 2014 version 5.3.0.17 (Van Zandvoort, 2014). The qualitative data was 
further used to write descriptive case studies. The scores obtained from the two FSFI subscales 
were used to assess changes in desire and arousal across time and scores obtained from the FSDS-
R Item 13 were utilised to assess changes in distress related to low sexual desire.  These changes 
were represented graphically. Due to the small sample size and qualitative nature of the cases no 
statistical analysis was done. 
 
RESULTS 
Thirteen participants were recruited; nine completed the study. Two participants were disqualified 
at the end of the first consultation and no prescription was given and two participants withdrew 
from the study.  
 
Information obtained from the FSFI subscales as well as Item 13 of the FSDS-R is represented 
graphically in order to demonstrate any changes in sexual desire, sexual arousal, and distress 
related to low sexual desire across time. The desire domain of the FSFI consists of two items. The 
first item measures the frequency of sexual desire over the preceding four weeks, while the second 
item measures the level or intensity of sexual desire. (Gerstenberger, 2010:3101). The minimum 
score possible for this subscale is 2 and the maximum score possible is 10. A score of 5 and below 
for the desire subscale indicates sexual dysfunction, while a score of 6 and above indicates the 
absence of sexual dysfunction (Gerstenberger, 2010:3098). 
 
The arousal domain of the FSFI contains four items. The minimum score possible for this subscale 
is zero and the maximum score possible is 20. A score of zero for the arousal subscale indicates 
no sexual activity during the preceding four weeks, but provides no further information. According 
to Maserejian et al. (2012:45) a score of 1 for question 4 of this subscale indicates the presence of 
arousal problems. The lower the score obtained in the particular FSFI subscale, the higher the 
degree of sexual dysfunction in that particular domain.  
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The maximum score possible for Item 13 of the FSDS-R is 4 and the minimum score possible is 
zero. A higher score indicates a higher level of distress, while a score of zero indicates no distress 
related to low sexual desire. 
 
Changes in Sexual Desire  
Information obtained by means of the sexual desire subscale of the FSFI revealed the following: 
 At the time of the first consultation, all nine participants obtained scores of 5 or below for this 
subscale, confirming the presence of low desire. Six of the participants obtained a score of 2, 
which is the minimum score possible.  
 By the final consultation, seven participants (78% of participants) obtained scores of 6 and 
above for this subscale, indicating a successful therapeutic outcome.  
 
Figure 1 below graphically illustrates the mean score rating for all participants for the desire 
subscale of the FSFI during the course of the study. By the second consultation (week four), the 
average score was still below 5. An average score of 6, indicating a successful therapeutic 
outcome, was reached by the third consultation (week eight). The final average score of 6 obtained 
at the fourth and final consultation (week 12), indicates that individualised homeopathic treatment 
may be beneficial in alleviating low sexual desire in perimenopause.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Average scores obtained for the desire subscale of the FSFI during the course of 
the study 
 
1st Consultation 2nd Consultation 3rd Consultation Final Consultation
Desire 2 4 6 6
2
4
6 6
0
1
2
3
4
5
6
7
Desire Subscale of the FSFI
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Changes in Sexual Arousal 
Information obtained by means of the arousal subscale of the FSFI revealed the following: 
 At the time of the first consultation only one participant obtained a score of 1 for question 4, 
indicating the presence of arousal difficulties (Maserejian et al., 2012:5).  
 By the second consultation a second participant obtained a score of 1 for question 4. This 
particular participant obtained a score of zero at the first consultation due to no sexual activity 
taking place during the four weeks prior to the first consultation. 
 By the third and fourth consultations none of the participants obtained a score of 1 for question 
4. No arousal problems were therefore considered to be present by the end of the treatment 
period. 
 
Figure 2 below graphically illustrates the average scores obtained for question 4 of the arousal 
subscale of the FSFI during the course of the study. Scores of zero, indicating that no sexual 
activity took place during the preceding four weeks, were not included in the total average scores. 
At the time of the first consultation the average score for question 4 was 3 out of a maximum 
possible score of 5. By the second consultation the average score had increased to 4, where it 
remained for the duration of the study. The average score well above 1 for question 4 of the arousal 
subscale indicates that arousal difficulties were not prevalent among the sample group. 
 
 
 
Figure 2: Average scores obtained for question 4 of the arousal subscale of the FSFI during 
the course of the study 
1st Consultation 2nd Consultation 3rd Consultation Final Consultation
Question 4 3 4 4 4
3
4 4 4
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
Question 4 of the Arousal Subscale of the FSFI
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Figure 3 below graphically illustrates the average scores for all participants obtained for the arousal 
subscale of the FSFI during the course of the study. Scores of zero, indicating that no sexual 
activity took place, were not included in the total average scores. The results show a gradual 
increase (10% at a time) in the average score until the third consultation. By the time of the fourth 
consultation there is a slight decrease (10%) in the average score, but the score remained slightly 
higher (10%) than pre-treatment scores. The small variation in scores across time could be due to 
the low incidence of arousal difficulties in the sample group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Average scores obtained for the arousal subscale of the FSFI during the course of 
the study 
 
Changes in Distress Related to Low Sexual Desire 
Information obtained by means of Item 13 of the FSDS-R showed the following: 
 At the time of the first consultation, all nine participants reported some level of distress related 
to their low sexual desire. 
 By the final consultation only one participant reported frequently feeling distressed and one 
reported always feeling distressed by low sexual desire. 
 
Figure 4 below graphically illustrates the average scores obtained for Item 13 of the FSDS-R 
during the course of the study. The marked decline in the total average score shows that 
individualised homeopathic treatment was beneficial in alleviating distress related to low sexual 
desire. 
1st Consultation 2nd Consultation 3rd Consultation Final Consultation
Arousal 12 14 16 14
12
14
16
14
0
2
4
6
8
10
12
14
16
18
Arousal Subscale of the FSFI
11 
 
 
Figure 4: Average scores obtained for Item 13 of the FSDS-R during the course of the study  
 
Remedy Frequency 
During the course of the study some remedies were prescribed more frequently than others. Table 
1 provides a summary of the remedies and potencies prescribed during the course of the study. 
 
Remedy Name and Potency: Number of Prescriptions: 
Lycopodium clavatum LM1 1 
Mercurius solubilis 6cH 3 
Natrum muriaticum 6cH 2 
Natrum muriaticum 30cH 1 
Natrum muriaticum LM1 1 
Nux vomica 30cH 2 
Nux vomica 200cH 1 
Sepia officinalis 30cH 7 
Sepia officinalis LM1 1 
Sulphur 6cH 1 
Sulphur 30cH 2 
Sulphur 200cH 1 
Sulphur LM potencies 4 
 
Table 1: Summary of remedies prescribed during the course of the study  
1st Consultation 2nd Consultation 3rd Consultation Final Consultation
Distress 3 2 1 1
3
2
1 1
0
0.5
1
1.5
2
2.5
3
3.5
Distress Related to Low Sexual Desire: Item 13 of the FSDS-R
Distress
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DISCUSSION 
Trends Observed 
Low Sexual Desire 
At the start of the study all nine participants obtained scores below 5 for the desire subscale of the 
FSFI, verifying that all participants suffered from low sexual desire. At the time of the second 
consultation (week four), only two participants (one and six) obtained scores of 6 and above (a 
successful therapeutic outcome) for the desire subscale, while the remaining seven participants all 
continued to obtain scores of 5 and below. By the third consultation (week eight), four participants 
(one, three, four and nine) obtained scores of 6 and above, while four participants (two, five, six 
and eight) obtained scores of 5 and below. Participant seven was not available at week eight and 
therefore did not complete the relevant questionnaires. At the time of the final consultation (week 
12) seven participants obtained scores of 6 and above while only two participants (two and five), 
continued to obtain scores of 5 and below. An unsuccessful therapeutic outcome was therefore 
observed in two cases. 
 
Sexual Arousal  
The mean score obtained for question 4 of the arousal subscale over the 12 week period indicates 
that arousal difficulties were uncommon in this sample group. 
 
Distress Related to Low Sexual Desire 
Scores obtained by means of Item 13 of the FSDS-R indicate that all nine participants experienced 
some level of distress related to their low sexual function at the start of the study. In six of the 
seven cases where a successful therapeutic outcome was observed, the expected pattern of a 
decrease in distress, coinciding with an increase in sexual desire, was noted. One participant 
deviated from this pattern as she obtained a score of 2 for Item 13 at both the first as well as the 
final consultation, despite her sexual desire scores increasing from 2 to 6 during the course of the 
study. This may be explained by the fact that, while her sexual function had definitely shown 
improvement during the course of the treatment, her sexual desire had not reached normal pre-
menopausal levels yet and was still causing her some distress. Her distress score was also not 
excessively high to begin with, indicating only occasional distress.  
 
Homeopathic Prescriptions 
Certain remedies and certain potencies were indicated more frequently than others. Some remedies 
also proved to be more effective in alleviating low sexual desire and other perimenopausal 
symptoms.  
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Commonly Prescribed Remedies 
The two most frequently prescribed remedies were Sulphur and Sepia officinalis, with a total of 
eight prescriptions each during the study period. This was followed by Natrum muriaticum with a 
total of four prescriptions. 
 
Commonly Prescribed Potencies  
The two most frequently prescribed potencies were 30cH, with 12 prescriptions, and LM potencies 
with seven prescriptions. Six prescriptions were written for 6cH potencies and only two for 200cH.  
 
Effective Remedies 
The remedy demonstrating the highest number of successful therapeutic outcomes is Sulphur, 
prescribed in three of the seven cases where a successful therapeutic outcome was observed. In 
one of the three cases Sulphur proved successful in a 6cH, in another case LM potencies were 
used, and in the third case Sulphur proved successful in a 30cH. Sepia officinalis 30cH follows 
closely, demonstrating efficacy in two out of the seven successful cases. In the remaining two 
successful cases, Natrum muriaticum and Mercurius solubilis were prescribed, proving effective 
in one case each.  
 
On repertorisation Sulphur, Sepia officinalis and Natrum muriaticum all scored a 3 for the rubric 
Female, sexual, libido, desire, diminished and are therefore strongly indicated for this symptom. 
Mercurius solubilis however did not score for this rubric, yet produced a successful therapeutic 
outcome. This can once again be explained by the fact that low sexual desire is a multifactorial 
problem influenced by mental, emotional and physical factors. As the participant’s energy levels, 
mood and general well-being improved during the course of the study, so also did her sexual desire. 
 
Other Factors Affecting Results 
It is possible that factors other than the prescribed individualised homeopathic remedy could have 
influenced the results. 
 
Relationship Factors 
The focus of the study was on low sexual desire as a symptom of perimenopause and the researcher 
therefore deliberately did not explore existing relationship problems. Only information 
spontaneously offered by participants were included in the write-up of case histories in chapter 
four, and participants were not prompted for any further information regarding difficulties in their 
relationships with their sexual partners. It is therefore not clear what influence, if any, relationship 
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factors had on the results obtained in this study. Future studies exploring female sexual function 
should therefore consider the effect of relationship factors on female sexuality. 
 
Sample Size and Duration of the Study 
The sample size of the study was small and the results can therefore not be generalised to the larger 
population (low external validity). A larger sample size will also be more amenable to statistical 
analysis. As low sexual desire is a complex, multifactorial problem, a longer study duration might 
have demonstrated better results. The study also did not explore whether the amelioration of 
symptoms obtained during the study period were maintained after the cessation of treatment. 
 
The Homeopathic Consultation 
According to Steinkopf (2015:1), the placebo effect in medicine does not only refer to a therapeutic 
response to an inert treatment, but also includes additional aspects of medical treatment such as a 
positive doctor-patient relationship. Research shows that certain aspects of the homeopathic 
consultation itself, such as openness, sensitivity and a non-judgmental attitude demonstrated by 
the practitioner, can produce a powerful therapeutic effect in for example rheumatoid arthritis 
patients (Brien et al., 2012:514). Even though all the participants in this study received an active 
homeopathic remedy, the intrinsic nature of the homeopathic case-taking itself could therefore 
have produced a placebo effect and contributed to the positive results. 
  
The Hawthorne Effect 
According to McCambridge et al. (2014:268), the Hawthorne effect in research refers to the 
phenomenon that the awareness of being studied or having one’s behaviour evaluated can lead to 
changes in behaviour in order to please the researcher. Observational and non-blinded studies are 
especially vulnerable to the Hawthorne Effect (Fernald et al., 2012:83). Due to the qualitative 
nature of the study considerable interaction took place between the researcher and the participants, 
which may have rendered the study susceptible to the Hawthorne Effect.  
 
CONCLUSION 
The aim of this study was to determine the effect of individualised homeopathic treatment on low 
sexual desire in perimenopause. 
 
This embedded mixed method case study design took place over a period of 12 weeks and 
consisted of four consultations per participant at four week intervals. A complete case history was 
taken and participants completed the desire and arousal subscales of the FSFI, as well as Item 13 
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of the FSDS-R, at each of the four consultations. A single individualised homeopathic remedy was 
prescribed for each participant in accordance with the principles of classical homeopathy. No 
adverse effects were noted during the course of the study. 
 
The results of this small pilot study suggest that individualised homeopathic treatment was 
effective in alleviating low sexual desire in seven out of nine perimenopausal females between the 
ages of 40 and 60 years old. At the end of the study seven participants obtained scores of 6 and 
above for the desire subscale of the FSFI, indicating a successful therapeutic outcome. The results 
also appear to confirm the beneficial effect of individualised homeopathic treatment on the 
additional symptoms associated with perimenopause. In order to verify the results, the study 
should be repeated using a larger sample group over a longer period of time.  
 
This study contributed to the body of homeopathic knowledge by demonstrating effectiveness in 
an area that remains under-researched and provides a basis for future research on the effect of 
homeopathy on low sexual desire in females. 
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